FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Martin Fromm

Research Profile

Chemicals & Drugs

Physiology

Anatomy

Genes & Molecular Sequences

Concepts & Ideas

Co-author Network

Publications

TOP 3
Sabine Klatt; Martin F Fromm; Jörg König
The influence of oral antidiabetic drugs on cellular drug uptake mediated by hepatic OATP family members.
Martin F Fromm; Renke Maas; Thomas Tümena; Karl G Gassmann
Potentially inappropriate medications in a large cohort of patients in geriatric units: association with clinical and functional characteristics.
Barbara Pfistermeister; Christian Schenk; Thomas Bürkle; Martin F Fromm; Johannes Kornhuber; Renke Maas
Different indications, warnings and precautions, and contraindications for the same drug--an international comparison of prescribing information for commonly used psychiatric drugs.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Martin Fromm (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Sabine Klatt; Martin F Fromm; Jörg König
The influence of oral antidiabetic drugs on cellular drug uptake mediated by hepatic OATP family members.
Basic & clinical pharmacology & toxicology 2013;112(4):244-50.
2013: Martin F Fromm; Renke Maas; Thomas Tümena; Karl G Gassmann
Potentially inappropriate medications in a large cohort of patients in geriatric units: association with clinical and functional characteristics.
European journal of clinical pharmacology 2013;69(4):975-84.
2013: Barbara Pfistermeister; Christian Schenk; Thomas Bürkle; Martin F Fromm; Johannes Kornhuber; Renke Maas
Different indications, warnings and precautions, and contraindications for the same drug--an international comparison of prescribing information for commonly used psychiatric drugs.
Pharmacoepidemiology and drug safety 2013;22(3):329-33.
2013: Oliver Zolk; Martin F Fromm; Heinrich Iro; Marc Muschler; Rebecca Schnepf; Maximilian Traxdorf; Olaf Wendler; Johannes Zenk
Transporter gene expression in human head and neck squamous cell carcinoma and associated epigenetic regulatory mechanisms.
The American journal of pathology 2013;182(1):234-43.
2012: Martin F Fromm
Prediction of transporter-mediated drug-drug interactions using endogenous compounds.
Clinical pharmacology and therapeutics 2012;92(5):546-8.
2012: Joachim Strobel; Maren Mieth; Daniel Auge; Beate Endress; Martin F Fromm; Jörg König; Renke Maas
Interaction of the cardiovascular risk marker asymmetric dimethylarginine (ADMA) with the human cationic amino acid transporter 1 (CAT1).
Journal of molecular and cellular cardiology 2012;53(3):392-400.
2012: Jörg König; Sabine Klatt; Karin Dilger; Martin F Fromm
Characterization of ursodeoxycholic and norursodeoxycholic acid as substrates of the hepatic uptake transporters OATP1B1, OATP1B3, OATP2B1 and NTCP.
Basic & clinical pharmacology & toxicology 2012;111(2):81-6.
2012: Kathrin Mandery; Ingrid Schmidt; Bettina Balk; Krystyna Bujok; Martin F Fromm; Hartmut Glaeser
Inhibition of hepatic uptake transporters by flavonoids.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2012;46(1-2):79-85.
2012: Oliver Zolk; Martin F Fromm; Christian Ott; Roland E Schmieder
Effect of the rs168924 single-nucleotide polymorphism in the SLC6A2 catecholamine transporter gene on blood pressure in Caucasians.
Journal of clinical hypertension (Greenwich, Conn.) 2012;14(5):293-8.
2012: Oliver Zolk; Martin F Fromm
Drug transporter regulation in tumors by DNA methylation.
Genome medicine 2012;4(1):10.
2011: Thomas F Solbach; Martin F Fromm; Markus Grube; Oliver Zolk
Organic cation transporter 3: expression in failing and nonfailing human heart and functional characterization.
Journal of cardiovascular pharmacology 2011;58(4):409-17.
2011: Kathrin Mandery; Ingrid Schmidt; Heinrich Sticht; Bettina Balk; Krystyna Bujok; Christina Fahrmayr; Martin F Fromm; Hartmut Glaeser
Functional and structural relevance of conserved positively charged lysine residues in organic anion transporting polypeptide 1B3.
Molecular pharmacology 2011;80(3):400-6.
2011: Fabian Müller; Martin F Fromm
Transporter-mediated drug-drug interactions.
Pharmacogenomics 2011;12(7):1017-37.
2011: Fabian Müller; Ingrid Schmidt; Oliver Zolk; Martin F Fromm; Hartmut Glaeser; Jörg König; Renke Maas
Molecular mechanism of renal tubular secretion of the antimalarial drug chloroquine.
Antimicrobial agents and chemotherapy 2011;55(7):3091-8.
2011: Oliver Zolk; Martin F Fromm
Transporter-mediated drug uptake and efflux: important determinants of adverse drug reactions.
Clinical pharmacology and therapeutics 2011;89(6):798-805.
2011: Jörg König; Hartmut Glaeser; Markus Keiser; Kathrin Mandery; Ulrich Klotz; Martin F Fromm
Role of organic anion-transporting polypeptides for cellular mesalazine (5-aminosalicylic acid) uptake.
Drug metabolism and disposition: the biological fate of chemicals 2011;39(6):1097-102.
2011: Juergen Kindla; Fabian Müller; Maren Mieth; Martin F Fromm; Jörg König
Influence of non-steroidal anti-inflammatory drugs on organic anion transporting polypeptide (OATP) 1B1- and OATP1B3-mediated drug transport.
Drug metabolism and disposition: the biological fate of chemicals 2011;39(6):1047-53.
2011: Juergen Kindla; Tilman T Rau; Rudolf Jung; Peter A Fasching; Reiner Strick; Robert Stoehr; Arndt Hartmann; Martin F Fromm; Jörg König
Expression and localization of the uptake transporters OATP2B1, OATP3A1 and OATP5A1 in non-malignant and malignant breast tissue.
Cancer biology & therapy 2011;11(6):584-91.
2010: Kathrin Mandery; Krystyna Bujok; Ingrid Schmidt; Markus Keiser; Werner Siegmund; Bettina Balk; Jörg König; Martin F Fromm; Hartmut Glaeser
Influence of the flavonoids apigenin, kaempferol, and quercetin on the function of organic anion transporting polypeptides 1A2 and 2B1.
Biochemical pharmacology 2010;80(11):1746-53.
2010: Maren Poguntke; Eszter Hazai; Martin F Fromm; Oliver Zolk
Drug transport by breast cancer resistance protein.
Expert opinion on drug metabolism & toxicology 2010;6(11):1363-84.
2010: Christina Fahrmayr; Martin F Fromm; Jörg König
Hepatic OATP and OCT uptake transporters: their role for drug-drug interactions and pharmacogenetic aspects.
Drug metabolism reviews 2010;42(3):380-401.
2010: Michaela E Kraft; Hartmut Glaeser; Kathrin Mandery; Jörg König; Daniel Auge; Martin F Fromm; Ursula Schlötzer-Schrehardt; Ulrich Welge-Lüssen; Friedrich E Kruse; Oliver Zolk
The prostaglandin transporter OATP2A1 is expressed in human ocular tissues and transports the antiglaucoma prostanoid latanoprost.
Investigative ophthalmology & visual science 2010;51(5):2504-11.
2010: Hartmut Glaeser; K Mandery; H Sticht; Martin F Fromm; Jörg König
Relevance of conserved lysine and arginine residues in transmembrane helices for the transport activity of organic anion transporting polypeptide 1B3.
British journal of pharmacology 2010;159(3):698-708.
2010: Ulrike Werner; Dierk Werner; Svetlana Heinbüchner; Bernhard Graf; Hüseyin Ince; Stefan Kische; Petra Thürmann; Jörg König; Martin F Fromm; Oliver Zolk
Gender is an important determinant of the disposition of the loop diuretic torasemide.
Journal of clinical pharmacology 2010;50(2):160-8.
2010: Kathrin Mandery; Krystyna Bujok; Ingrid Schmidt; Thomas Wex; Gerhard Treiber; Peter Malfertheiner; Tilman T Rau; Kerstin U Amann; Kay Brune; Martin F Fromm; Hartmut Glaeser
Influence of cyclooxygenase inhibitors on the function of the prostaglandin transporter organic anion-transporting polypeptide 2A1 expressed in human gastroduodenal mucosa.
The Journal of pharmacology and experimental therapeutics 2010;332(2):345-51.
2009: Iouri Bachmakov; Hartmut Glaeser; B Endress; F Mörl; Jörg König; Martin F Fromm
Interaction of beta-blockers with the renal uptake transporter OCT2.
Diabetes, obesity & metabolism 2009;11(11):1080-3.
2009: S Klein; Oliver Zolk; Martin F Fromm; Falk Schrödl; Winfried Neuhuber; C Kryschi
Functionalized silicon quantum dots tailored for targeted siRNA delivery.
Biochemical and biophysical research communications 2009;387(1):164-8.
2009: J E Keskitalo; O Zolk; Martin F Fromm; K J Kurkinen; Pertti J Neuvonen; Mikko Niemi
ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin.
Clinical pharmacology and therapeutics 2009;86(2):197-203.
2009: Oliver Zolk; Thomas F Solbach; Jörg König; Martin F Fromm
Functional characterization of the human organic cation transporter 2 variant p.270Ala>Ser.
Drug metabolism and disposition: the biological fate of chemicals 2009;37(6):1312-8.
2009: Jürgen Kindla; Martin F Fromm; Jörg König
In vitro evidence for the role of OATP and OCT uptake transporters in drug-drug interactions.
Expert opinion on drug metabolism & toxicology 2009;5(5):489-500.
2009: Oliver Zolk; Thomas F Solbach; Jörg König; Martin F Fromm
Structural determinants of inhibitor interaction with the human organic cation transporter OCT2 (SLC22A2).
Naunyn-Schmiedeberg's archives of pharmacology 2009;379(4):337-48.
2009: Thomas Rau; Henrike Wuttke; L M Michels; Ulrike Werner; K Bergmann; M Kreft; Martin F Fromm; Thomas Eschenhagen
Impact of the CYP2D6 genotype on the clinical effects of metoprolol: a prospective longitudinal study.
Clinical pharmacology and therapeutics 2009;85(3):269-72.
2008: Oliver Zolk; Thomas F Solbach; Thomas Eschenhagen; Alexander Weidemann; Martin F Fromm
Activation of negative regulators of the hypoxia-inducible factor (HIF) pathway in human end-stage heart failure.
Biochemical and biophysical research communications 2008;376(2):315-20.
2008: Stefan Oswald; Jörg König; Dieter Lütjohann; Thomas Giessmann; Heyo K Kroemer; Christian Rimmbach; Dieter Rosskopf; Martin F Fromm; Werner Siegmund
Disposition of ezetimibe is influenced by polymorphisms of the hepatic uptake carrier OATP1B1.
Pharmacogenetics and genomics 2008;18(7):559-68.
2008: Iouri Bachmakov; Hartmut Glaeser; Martin F Fromm; Jörg König
Interaction of oral antidiabetic drugs with hepatic uptake transporters: focus on organic anion transporting polypeptides and organic cation transporter 1.
Diabetes 2008;57(6):1463-9.
2008: Thomas F Solbach; Barbara Paulus; Michael Weyand; Thomas Eschenhagen; Oliver Zolk; Martin F Fromm
ATP-binding cassette transporters in human heart failure.
Naunyn-Schmiedeberg's archives of pharmacology 2008;377(3):231-43.
2008: Daniel Janke; Sherif Mehralivand; Dennis Strand; Ute Gödtel-Armbrust; Alice Habermeier; Ulrike Gradhand; Christine Fischer; Mohammad R Toliat; Peter Fritz; Uli Zanger; Matthias Schwab; Martin F Fromm; Peter Nürnberg; Leszek Wojnowski; Ellen I Closs; Thomas Lang
6-mercaptopurine and 9-(2-phosphonyl-methoxyethyl) adenine (PMEA) transport altered by two missense mutations in the drug transporter gene ABCC4.
Human mutation 2008;29(5):659-69.
2008: Hartmut Glaeser; Martin F Fromm
Animal models and intestinal drug transport.
Expert opinion on drug metabolism & toxicology 2008;4(4):347-61.
2008: Charalampos Dragonas; Jan T Wagner; HJ Heppner; Thomas Bertsch; Wolfgang Mühlberg; S Wicklein; Andreas Pahl; Christine Diewald; Iouri Bachmakov; Cornel C Sieber; Martin F Fromm
The association of ABCB1 polymorphisms and elevated serum digitoxin concentrations in geriatric patients.
European journal of clinical pharmacology 2008;64(4):367-72.
2008: Annick Seithel; Kathrin Klein; Uli Zanger; Martin F Fromm; Jörg König
Non-synonymous polymorphisms in the human SLCO1B1 gene: an in vitro analysis of SNP c.1929A>C.
Molecular genetics and genomics : MGG 2008;279(2):149-57.
2008: U Gradhand; T Lang; Elke Schaeffeler; Hartmut Glaeser; Heike Tegude; Kathrin Klein; P Fritz; Gabriele Jedlitschky; H K Kroemer; Iouri Bachmakov; Birgit Anwald; Reinhold Kerb; Uli Zanger; Michel Eichelbaum; M Schwab; Martin F Fromm
Variability in human hepatic MRP4 expression: influence of cholestasis and genotype.
The pharmacogenomics journal 2008;8(1):42-52.
2008: Annick Seithel; Hartmut Glaeser; Martin F Fromm; Jörg König
The functional consequences of genetic variations in transporter genes encoding human organic anion-transporting polypeptide family members.
Expert opinion on drug metabolism & toxicology 2008;4(1):51-64.
2007: Martin F Fromm; Helmut Schwilden; Iouri Bachmakov; Jörg König; Frank Bremer; Jürgen Schüttler
Impact of the CYP3A5 genotype on midazolam pharmacokinetics and pharmacodynamics during intensive care sedation.
European journal of clinical pharmacology 2007;63(12):1129-33.
2007: Burkhard Hinz; Olga Cheremina; Jouri Bachmakov; Bertold Renner; Oliver Zolk; Martin F Fromm; Kay Brune
Dipyrone elicits substantial inhibition of peripheral cyclooxygenases in humans: new insights into the pharmacology of an old analgesic.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2007;21(10):2343-51.
2007: Annick Seithel; Sonja Eberl; Katrin Singer; Daniel Auge; Georg Heinkele; Nadine B Wolf; Frank Dörje; Martin F Fromm; Jörg König
The influence of macrolide antibiotics on the uptake of organic anions and drugs mediated by OATP1B1 and OATP1B3.
Drug metabolism and disposition: the biological fate of chemicals 2007;35(5):779-86.
2007: Ulrike Gradhand; Heike Tegude; Oliver Burk; Michel Eichelbaum; Martin F Fromm; Jörg König
Functional analysis of the polymorphism -211C>T in the regulatory region of the human ABCC3 gene.
Life sciences 2007;80(16):1490-4.
2007: Oliver Zolk; Johannes Jacobi; Andreas Pahl; Martin F Fromm; Roland E Schmieder
MDR1 genotype-dependent regulation of the aldosterone system in humans.
Pharmacogenetics and genomics 2007;17(2):137-44.
2007: Sonja Eberl; Bertold Renner; Antje Neubert; Mareike Reisig; Iouri Bachmakov; Jörg König; Frank Dörje; Thomas E Mürdter; Andreas Ackermann; Harald Dormann; Karl G Gassmann; Eckhart Hahn; Stefanie Zierhut; Kay Brune; Martin F Fromm
Role of p-glycoprotein inhibition for drug interactions: evidence from in vitro and pharmacoepidemiological studies.
Clinical pharmacokinetics 2007;46(12):1039-49.
2007: Svitlana Igel; Siegfried Drescher; Thomas E Mürdter; ute hofmann; Georg Heinkele; Heike Tegude; Hartmut Glaeser; Stefanie S Brenner; Andrew A Somogyi; Taher Omari; Christian Schäfer; Michel Eichelbaum; Martin F Fromm
Increased absorption of digoxin from the human jejunum due to inhibition of intestinal transporter-mediated efflux.
Clinical pharmacokinetics 2007;46(9):777-85.
2006: Ulrike Werner; C Lamprecht; Dierk Werner; Simon Schaefer; Henrike Wuttke; Burkhard Hinz; Martin F Fromm; Kay Brune
Valdecoxib does not interfere with the CYP2D6 substrate metoprolol.
International journal of clinical pharmacology and therapeutics 2006;44(9):397-400.
2006: Mikko Niemi; Kari T Kivistö; Ulf Diczfalusy; Karl Bodin; Leif Bertilsson; Martin F Fromm; Michel Eichelbaum
Effect of SLCO1B1 polymorphism on induction of CYP3A4 by rifampicin.
Pharmacogenetics and genomics 2006;16(8):565-8.
2006: Norbert Thuerauf; Martin F Fromm
The role of the transporter P-glycoprotein for disposition and effects of centrally acting drugs and for the pathogenesis of CNS diseases.
European archives of psychiatry and clinical neuroscience 2006;256(5):281-6.
2006: Iouri Bachmakov; Ulrike Werner; Beate Endress; Daniel Auge; Martin F Fromm
Characterization of beta-adrenoceptor antagonists as substrates and inhibitors of the drug transporter P-glycoprotein.
Fundamental & clinical pharmacology 2006;20(3):273-82.
2006: Laurent Becquemont; Hartmut Glaeser; Siegfried Drescher; Monika Hitzl; Nicolas Simon; Thomas E Murdter; Georg Heinkele; ute hofmann; Christian Schaefer; Oliver Burk; Céline Verstuyft; Michel Eichelbaum; Martin F Fromm
Effects of ursodeoxycholic acid on P-glycoprotein and cytochrome P450 3A4-dependent pharmacokinetics in humans.
Clinical pharmacology and therapeutics 2006;79(5):449-60.
2006: Jörg König; Annick Seithel; Ulrike Gradhand; Martin F Fromm
Pharmacogenomics of human OATP transporters.
Naunyn-Schmiedeberg's archives of pharmacology 2006;372(6):432-43.
2006: Thomas F Solbach; Jörg König; Martin F Fromm; Oliver Zolk
ATP-binding cassette transporters in the heart.
Trends in cardiovascular medicine 2006;16(1):7-15.
2005: Olga Cheremina; Iouri Bachmakov; Antje Neubert; Kay Brune; Martin F Fromm; Burkhard Hinz
Simultaneous determination of oxycodone and its major metabolite, noroxycodone, in human plasma by high-performance liquid chromatography.
Biomedical chromatography : BMC 2005;19(10):777-82.
2005: Martin F Fromm; Bernhard M W Schmidt; Andreas Pahl; Johannes Jacobi; Roland E Schmieder
CYP3A5 genotype is associated with elevated blood pressure.
Pharmacogenetics and genomics 2005;15(10):737-41.
2005: Christoph Lamprecht; Ulrike Werner; Dierk Werner; Simon Schaefer; Bertold Renner; Martin F Fromm; Kay Brune
Effect of selective cyclooxygenase-2 inhibitors on heart rate in healthy young men.
The American journal of cardiology 2005;95(12):1531-2.
2005: Oliver Burk; Katja A Arnold; Andreas K Nussler; Elke Schaeffeler; Ekaterina Efimova; Bonnie A Avery; Mitchell A Avery; Martin F Fromm; Michel Eichelbaum
Antimalarial artemisinin drugs induce cytochrome P450 and MDR1 expression by activation of xenosensors pregnane X receptor and constitutive androstane receptor.
Molecular pharmacology 2005;67(6):1954-65.
2005: Mikko Niemi; Kari T Kivistö; ute hofmann; Matthias Schwab; Michel Eichelbaum; Martin F Fromm
Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1).
British journal of clinical pharmacology 2005;59(5):602-4.
2005: Ute I Schwarz; Diana Seemann; Reinhard Oertel; Stephan Miehlke; Eberhard Kuhlisch; Martin F Fromm; Richard B Kim; David G Bailey; Wilhelm Kirch
Grapefruit juice ingestion significantly reduces talinolol bioavailability.
Clinical pharmacology and therapeutics 2005;77(4):291-301.
2005: Iouri Bachmakov; Sabine Rekersbrink; ute hofmann; Michel Eichelbaum; Martin F Fromm
Characterisation of (R/S)-propafenone and its metabolites as substrates and inhibitors of P-glycoprotein.
Naunyn-Schmiedeberg's archives of pharmacology 2005;371(3):195-201.
2005: Hartmut Glaeser; Siegfried Drescher; Michel Eichelbaum; Martin F Fromm
Influence of rifampicin on the expression and function of human intestinal cytochrome P450 enzymes.
British journal of clinical pharmacology 2005;59(2):199-206.
2005: Kari T Kivistö; Mikko Niemi; Elke Schaeffeler; Kaisu Pitkälä; Reijo S Tilvis; Martin F Fromm; Matthias Schwab; Florian Lang; Michel Eichelbaum; Timo Strandberg
CYP3A5 genotype is associated with diagnosis of hypertension in elderly patients: data from the DEBATE Study.
American journal of pharmacogenomics : genomics-related research in drug development and clinical practice 2005;5(3):191-5.
2004: Kari T Kivistö; Mikko Niemi; Martin F Fromm
Functional interaction of intestinal CYP3A4 and P-glycoprotein.
Fundamental & clinical pharmacology 2004;18(6):621-6.
2004: Dierk Werner; Henrike Wuttke; Martin F Fromm; Simon Schaefer; Thomas Eschenhagen; Kay Brune; Werner G Daniel; Ulrike Werner
Effect of amiodarone on the plasma levels of metoprolol.
The American journal of cardiology 2004;94(10):1319-21.
2004: Karin Dilger; Matthias Schwab; Martin F Fromm
Identification of budesonide and prednisone as substrates of the intestinal drug efflux pump P-glycoprotein.
Inflammatory bowel diseases 2004;10(5):578-83.
2004: Hartmut Glaeser; Siegfried Drescher; ute hofmann; Georg Heinkele; Andrew A Somogyi; Michel Eichelbaum; Martin F Fromm
Impact of concentration and rate of intraluminal drug delivery on absorption and gut wall metabolism of verapamil in humans.
Clinical pharmacology and therapeutics 2004;76(3):230-8.
2004: Kari T Kivistö; Jörg Zukunft; ute hofmann; Mikko Niemi; Sabine Rekersbrink; Swetlana Schneider; Gerd Luippold; Matthias Schwab; Michel Eichelbaum; Martin F Fromm
Characterisation of cerivastatin as a P-glycoprotein substrate: studies in P-glycoprotein-expressing cell monolayers and mdr1a/b knock-out mice.
Naunyn-Schmiedeberg's archives of pharmacology 2004;370(2):124-30.
2004: Kari T Kivistö; Mikko Niemi; Elke Schaeffeler; Kaisu Pitkälä; Reijo S Tilvis; Martin F Fromm; Matthias Schwab; Michel Eichelbaum; Timo Strandberg
Lipid-lowering response to statins is affected by CYP3A5 polymorphism.
Pharmacogenetics 2004;14(8):523-5.
2004: Martin F Fromm
Importance of P-glycoprotein at blood-tissue barriers.
Trends in pharmacological sciences 2004;25(8):423-9.
2004: Mikko Niemi; Elke Schaeffeler; Thomas Lang; Martin F Fromm; Mikko Neuvonen; Carl Kyrklund; Janne T Backman; Reinhold Kerb; Matthias Schwab; Pertti J Neuvonen; Michel Eichelbaum; Kari T Kivistö
High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1).
Pharmacogenetics 2004;14(7):429-40.
2004: Monika Hitzl; Elke Schaeffeler; Berthold Hocher; Torsten Slowinski; Horst Halle; Michel Eichelbaum; Peter Kaufmann; Peter Fritz; Martin F Fromm; Matthias Schwab
Variable expression of P-glycoprotein in the human placenta and its association with mutations of the multidrug resistance 1 gene (MDR1, ABCB1).
Pharmacogenetics 2004;14(5):309-18.
2004: Michel Eichelbaum; Martin F Fromm; Matthias Schwab
Clinical aspects of the MDR1 (ABCB1) gene polymorphism.
Therapeutic drug monitoring 2004;26(2):180-5.
2004: Thomas Lang; Monika Hitzl; Oliver Burk; Esther Mornhinweg; Andrea Keil; Reinhold Kerb; Kathrin Klein; Uli Zanger; Michel Eichelbaum; Martin F Fromm
Genetic polymorphisms in the multidrug resistance-associated protein 3 (ABCC3, MRP3) gene and relationship to its mRNA and protein expression in human liver.
Pharmacogenetics 2004;14(3):155-64.
2004: Oliver Von Richter; Oliver Burk; Martin F Fromm; Klaus-Peter Thon; Michel Eichelbaum; Kari T Kivistö
Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens.
Clinical pharmacology and therapeutics 2004;75(3):172-83.
2003: Martin F Fromm
Importance of P-glycoprotein for drug disposition in humans.
European journal of clinical investigation 2003;33 Suppl 2():6-9.
2003: Florian Läpple; Oliver Von Richter; Martin F Fromm; Tanja Richter; Klaus-Peter Thon; Hermann Wisser; Ernst-Ulrich Griese; Michel Eichelbaum; Kari T Kivistö
Differential expression and function of CYP2C isoforms in human intestine and liver.
Pharmacogenetics 2003;13(9):565-75.
2003: Ulrike Werner; Dierk Werner; Thomas Rau; Martin F Fromm; Burkhard Hinz; Kay Brune
Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans.
Clinical pharmacology and therapeutics 2003;74(2):130-7.
2003: Siegfried Drescher; Hartmut Glaeser; Thomas E Mürdter; Monika Hitzl; Michel Eichelbaum; Martin F Fromm
P-glycoprotein-mediated intestinal and biliary digoxin transport in humans.
Clinical pharmacology and therapeutics 2003;73(3):223-31.
2003: Monika Hitzl; Kathrin Klein; Uli Zanger; Peter Fritz; Andreas K Nüssler; Peter Neuhaus; Martin F Fromm
Influence of omeprazole on multidrug resistance protein 3 expression in human liver.
The Journal of pharmacology and experimental therapeutics 2003;304(2):524-30.
2003: Mikko Niemi; Janne T Backman; Martin F Fromm; Pertti J Neuvonen; Kari T Kivistö
Pharmacokinetic interactions with rifampicin : clinical relevance.
Clinical pharmacokinetics 2003;42(9):819-50.
2003: Matthias Schwab; Elke Schaeffeler; Claudia Marx; Martin F Fromm; Bernd A Kaskas; Joerg Metzler; Eduard F Stange; Hans Herfarth; Juergen Schoelmerich; Michael Gregor; Siegfried Walker; Ingolf Cascorbi; Ivar Roots; Ulrich Brinkmann; Uli Zanger; Michel Eichelbaum
Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis.
Gastroenterology 2003;124(1):26-33.
2003: Matthias Schwab; Michel Eichelbaum; Martin F Fromm
Genetic polymorphisms of the human MDR1 drug transporter.
Annual review of pharmacology and toxicology 2003;43():285-307.
2002: Martin F Fromm
Genetically determined differences in P-glycoprotein function: implications for disease risk.
Toxicology 2002;181-182():299-303.
2002: Martin F Fromm
The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans.
Advanced drug delivery reviews 2002;54(10):1295-310.
2002: Andreas Johne; Karla Köpke; Thomas Gerloff; Ingrid Mai; Stephan Rietbrock; Christian Meisel; Sven Hoffmeyer; Reinhold Kerb; Martin F Fromm; Ulrich Brinkmann; Michel Eichelbaum; Jürgen Brockmöller; Ingolf Cascorbi; Ivar Roots
Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene.
Clinical pharmacology and therapeutics 2002;72(5):584-94.
2002: Dagmar Busse; Gudrun Würthwein; Christiane Hinske; Georg Hempel; Martin F Fromm; Michel Eichelbaum; Heyo K Kroemer; Friedrich W Busch
Pharmacokinetics of intravenous etoposide in patients with breast cancer: influence of dose escalation and cyclophosphamide and doxorubicin coadministration.
Naunyn-Schmiedeberg's archives of pharmacology 2002;366(3):218-25.
2002: Rajinder K Bhardwaj; Hartmut Glaeser; Laurent Becquemont; Ulrich Klotz; Suresh K Gupta; Martin F Fromm
Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4.
The Journal of pharmacology and experimental therapeutics 2002;302(2):645-50.
2002: Oliver Burk; Heike Tegude; Ina Koch; Elisabeth Hustert; Renzo Wolbold; Hartmut Glaeser; Kathrin Klein; Martin F Fromm; Andreas K Nuessler; Peter Neuhaus; Uli Zanger; Michel Eichelbaum; Leszek Wojnowski
Molecular mechanisms of polymorphic CYP3A7 expression in adult human liver and intestine.
The Journal of biological chemistry 2002;277(27):24280-8.
2002: Siegfried Drescher; Elke Schaeffeler; Monika Hitzl; ute hofmann; Matthias Schwab; Ulrich Brinkmann; Michel Eichelbaum; Martin F Fromm
MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine.
British journal of clinical pharmacology 2002;53(5):526-34.
2002: Hartmut Glaeser; Siegfried Drescher; Heiko van der Kuip; Christoph Behrens; Anke Geick; Oliver Burk; John Dent; Andrew Somogyi; Oliver Von Richter; Ernst-Ulrich Griese; Michel Eichelbaum; Martin F Fromm
Shed human enterocytes as a tool for the study of expression and function of intestinal drug-metabolizing enzymes and transporters.
Clinical pharmacology and therapeutics 2002;71(3):131-40.
2002: ute hofmann; Monika Seiler; Siegfried Drescher; Martin F Fromm
Determination of fexofenadine in human plasma and urine by liquid chromatography-mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2002;766(2):227-33.
2001: Martin F Fromm
[Unexpected high plasma level of drugs. Blocked transporter can be the cause].
MMW Fortschritte der Medizin 2001;143(51-52):36-7.
2001: Christiane Pauli-Magnus; Sabine Rekersbrink; Ulrich Klotz; Martin F Fromm
Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein.
Naunyn-Schmiedeberg's archives of pharmacology 2001;364(6):551-7.
2001: Oliver Von Richter; B Greiner; Martin F Fromm; R Fraser; T Omari; M L Barclay; J Dent; Andrew A Somogyi; Michel Eichelbaum
Determination of in vivo absorption, metabolism, and transport of drugs by the human intestinal wall and liver with a novel perfusion technique.
Clinical pharmacology and therapeutics 2001;70(3):217-27.
2001: Monika Hitzl; Siegfried Drescher; H van der Kuip; E Schäffeler; J Fischer; Matthias Schwab; Michel Eichelbaum; Martin F Fromm
The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells.
Pharmacogenetics 2001;11(4):293-8.
2001: Dagmar Busse; Martin F Fromm; Klaus Mörike; Siegfried Drescher; V Kühlkamp; Michel Eichelbaum
Disposition and pharmacologic effects of R/S-verapamil in patients with chronic atrial fibrillation: an investigation comparing single and multiple dosing.
Clinical pharmacology and therapeutics 2001;69(5):324-32.
2001: Christiane Pauli-Magnus; Thomas E Mürdter; A Godel; Thomas Mettang; Michel Eichelbaum; Ulrich Klotz; Martin F Fromm
P-glycoprotein-mediated transport of digitoxin, alpha-methyldigoxin and beta-acetyldigoxin.
Naunyn-Schmiedeberg's archives of pharmacology 2001;363(3):337-43.
2001: Dawood Darbar; Martin F Fromm; S Dellorto; Dan Mark Roden
Sympathetic activation enhances QT prolongation by quinidine.
Journal of cardiovascular electrophysiology 2001;12(1):9-14.
2000: Martin F Fromm; Hans-Martin Kauffmann; P Fritz; Oliver Burk; Heyo K Kroemer; Rolf Warzok; Michel Eichelbaum; Werner Siegmund; Dieter Schrenk
The effect of rifampin treatment on intestinal expression of human MRP transporters.
The American journal of pathology 2000;157(5):1575-80.
2000: Christiane Pauli-Magnus; Oliver Von Richter; Oliver Burk; A Ziegler; Thomas Mettang; Michel Eichelbaum; Martin F Fromm
Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein.
The Journal of pharmacology and experimental therapeutics 2000;293(2):376-82.
2000: Martin F Fromm
P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs.
International journal of clinical pharmacology and therapeutics 2000;38(2):69-74.
1999: Karin Dilger; B Greiner; Martin F Fromm; ute hofmann; Heyo K Kroemer; Michel Eichelbaum
Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6.
Pharmacogenetics 1999;9(5):551-9.
1999: M Cvetkovic; Brenda F Leake; Martin F Fromm; Grant R Wilkinson; Richard B Kim
OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine.
Drug metabolism and disposition: the biological fate of chemicals 1999;27(8):866-71.
1999: Martin F Fromm; Dawood Darbar; S Dell'Orto; Dan Mark Roden
Modulation of effect of dietary salt on prehepatic first-pass metabolism: effects of beta-blockade and intravenous salt loading.
The Journal of pharmacology and experimental therapeutics 1999;290(1):253-8.
1999: Richard B Kim; Cristoph Wandel; Brenda F Leake; M Cvetkovic; Martin F Fromm; Peter J Dempsey; M M Roden; FJ Belas; AK Chaudhary; Dan Mark Roden; Alastair J J Wood; Grant R Wilkinson
Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein.
Pharmaceutical research 1999;16(3):408-14.
1999: Martin F Fromm; Richard B Kim; C Michael Stein; Grant R Wilkinson; Dan Mark Roden
Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine [seecomments].
Circulation 1999;99(4):552-7.
1999: Martin F Fromm; B Leake; Dan Mark Roden; Grant R Wilkinson; Richard B Kim
Human MRP3 transporter: identification of the 5'-flanking region, genomic organization and alternative splice variants.
Biochimica et biophysica acta 1999;1415(2):369-74.
1998: Dawood Darbar; Martin F Fromm; S Dell'Orto; Richard B Kim; H K Kroemer; M Eichelbaum; Dan Mark Roden
Modulation by dietary salt of verapamil disposition in humans.
Circulation 1998;98(24):2702-8.
1998: Martin F Fromm; Karin Dilger; Dagmar Busse; Heyo K Kroemer; Michel Eichelbaum; Ulrich Klotz
Gut wall metabolism of verapamil in older people: effects of rifampicin-mediated enzyme induction.
British journal of clinical pharmacology 1998;45(3):247-55.
1998: Richard B Kim; Martin F Fromm; Cristoph Wandel; Brenda F Leake; Alastair J J Wood; Dan Mark Roden; Grant R Wilkinson
The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors.
The Journal of clinical investigation 1998;101(2):289-94.
1997: Martin F Fromm; K Eckhardt; S Li; G Schänzle; ute hofmann; Gerd Mikus; Michel Eichelbaum
Loss of analgesic effect of morphine due to coadministration of rifampin.
Pain 1997;72(1-2):261-7.
1996: N Holtbecker; Martin F Fromm; Heyo K Kroemer; E E Ohnhaus; H Heidemann
The nifedipine-rifampin interaction. Evidence for induction of gut wall metabolism.
Drug metabolism and disposition: the biological fate of chemicals 1996;24(10):1121-3.
1996: Martin F Fromm; Dagmar Busse; Heyo K Kroemer; Michel Eichelbaum
Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin.
Hepatology (Baltimore, Md.) 1996;24(4):796-801.
1996: K T Kivistö; G Bookjans; Martin F Fromm; Ernst-Ulrich Griese; Peter A Münzel; Heyo K Kroemer
Expression of CYP3A4, CYP3A5 and CYP3A7 in human duodenal tissue.
British journal of clinical pharmacology 1996;42(3):387-9.
1996: Heyo K Kroemer; Martin F Fromm; Michel Eichelbaum
Stereoselectivity in drug metabolism and action: effects of enzyme inhibition and induction.
Therapeutic drug monitoring 1996;18(4):388-92.
1995: Martin F Fromm; ute hofmann; Ernst-Ulrich Griese; Gerd Mikus
Dihydrocodeine: a new opioid substrate for the polymorphic CYP2D6 in humans.
Clinical pharmacology and therapeutics 1995;58(4):374-82.
1995: Martin F Fromm; Heyo K Kroemer
[Mirror, mirror on the wall--stereoselectivity of drug effects].
Fortschritte der Medizin 1995;113(24):343-5.
1995: ute hofmann; Martin F Fromm; S Johnson; Gerd Mikus
Simultaneous determination of dihydrocodeine and dihydromorphine in serum by gas chromatography-tandem mass spectrometry.
Journal of chromatography. B, Biomedical applications 1995;663(1):59-65.
1995: Martin F Fromm; S Botsch; G Heinkele; J Evers; Heyo K Kroemer
Influence of renal function on the steady-state pharmacokinetics of the antiarrhythmic propafenone and its phase I and phase II metabolites.
European journal of clinical pharmacology 1995;48(3-4):279-83.
1994: Heyo K Kroemer; Martin F Fromm; K Bühl; H Terefe; Gottfried Blaschke; Michel Eichelbaum
An enantiomer-enantiomer interaction of (S)- and (R)-propafenone modifies the effect of racemic drug therapy.
Circulation 1994;89(5):2396-400.
1993: H Thomas Schneider; Andrea May; Martin F Fromm; S Theobaldy; Eckhart Hahn; C Ell
Parameters influencing piezoelectric shock wave lithotripsy of biliary calculi.
The Journal of stone disease 1993;5(1):24-31.
1991: H Thomas Schneider; Martin F Fromm; R Ott; P Janowitz; W Swobodnik; H Neuhaus; C Ell
In vitro fragmentation of gallstones: comparison of electrohydraulic, electromagnetic and piezoelectric shockwave lithotripters.
Hepatology (Baltimore, Md.) 1991;14(2):301-5.